文献速递遗传性与小管间质肾病水电解质与酸碱

PMM2启动子突变导致多囊肾病伴高胰岛素性低血糖

Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase 2.
PubMed 文献 · J Am Soc Nephrol · 2017-04-03

研究在11个无关家庭的17名高胰岛素性低血糖(HI)合并先天性多囊肾病(PKD)患儿中,通过全基因组连锁分析发现16p13.2显著位点,并鉴定出PMM2启动子突变c.-167G>T。该突变与PMM2编码突变构成复合杂合或纯合,导致组织特异性PMM2缺陷,提出HIPKD为一种新的遗传病。

要点

  • HI合并PKD的患儿应警惕PMM2启动子突变c.-167G>T。
  • 该突变可不伴CDG1A典型表现,需与编码突变区分。
  • PMM2启动子突变可能通过影响ZNF143结合改变染色质环形成。

核心结论

  • PMM2启动子突变c.-167G>T是HIPKD的遗传基础,拓展了HI和PKD的遗传病因。

研究设计与样本

  • 对11个无关家庭的17名HIPKD患儿进行全基因组连锁分析及候选基因测序。

主要发现

  • 5个信息家庭全基因组连锁分析显示染色体16p13.2单一显著位点,LOD评分6.5。
  • 所有患者携带PMM2启动子突变c.-167G>T,纯合或与PMM2编码突变反式排列。
  • 患者肾脏细胞中该启动子突变与转录活性降低及转录因子ZNF143结合受损相关。
  • 体外培养胰腺β细胞去糖基化可改变胰岛素分泌。

关键数值与推荐

  • 连锁分析LOD评分为6.5(5个信息家庭)。
  • PMM2启动子突变为c.-167G>T。

临床怎么用

  • 对不明原因HI合并PKD的患儿,应检测PMM2启动子突变c.-167G>T。
  • 发现该突变时需注意患者可能无CDG1A典型神经系统表现。

局限性

  • 样本量小(17名患儿来自11个家庭),机制研究主要基于体外和计算机分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperinsulinemic hypoglycemia (HI) and congenital polycystic kidney disease (PKD) are rare, genetically heterogeneous disorders. The co-occurrence of these disorders (HIPKD) in 17 children from 11 unrelated families suggested an unrecognized genetic disorder. Whole-genome linkage analysis in five informative families identified a single significant locus on chromosome 16p13.2 (logarithm of odds score 6.5). Sequencing of the coding regions of all linked genes failed to identify biallelic mutations. Instead, we found in all patients a promoter mutation (c.-167G>T) in the phosphomannomutase 2 gene (PMM2), either homozygous or in trans with PMM2 coding mutations. PMM2 encodes a key enzyme in N-glycosylation. Abnormal glycosylation has been associated with PKD, and we found that deglycosylation in cultured pancreatic β cells altered insulin secretion. Recessive coding mutations in PMM2 cause congenital disorder of glycosylation type 1a (CDG1A), a devastating multisystem disorder with prominent neurologic involvement. Yet our patients did not exhibit the typical clinical or diagnostic features of CDG1A. In vitro, the PMM2 promoter mutation associated with decreased transcriptional activity in patient kidney cells and impaired binding of the transcription factor ZNF143. In silico analysis suggested an important role of ZNF143 for the formation of a chromatin loop including PMM2 We propose that the PMM2 promoter mutation alters tissue-specific chromatin loop formation, with consequent organ-specific deficiency of PMM2 leading to the restricted phenotype of HIPKD. Our findings extend the spectrum of genetic causes for both HI and PKD and provide insights into gene regulation and PMM2 pleiotropy.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cabezas OR, Flanagan SE, Stanescu H, et al. Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase 2. J Am Soc Nephrol. 2017. PMID: 28373276. doi:10.1681/ASN.2016121312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。